Cellular Biomedicine Pays $22 Million to Acquire Agreen Biotech of China

Cellular Biomedicine Group, a California-headquartered biotech with a China focus, will acquire Agreen Biotech of China for about $22 million, of which $3.3 million is cash and the remainder is CBMG stock. Both companies are involved in cellular therapeutics. Agreen owns IP-protected tests and preparation technologies for cellular immunotherapies that it is developing to treat tumors, infections and immune disorders. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //